PE20230859A1 - Formas de dosificacion oral solidas de combinacion de antagonistas de la hormona liberadora de gonadotropina - Google Patents
Formas de dosificacion oral solidas de combinacion de antagonistas de la hormona liberadora de gonadotropinaInfo
- Publication number
- PE20230859A1 PE20230859A1 PE2022002787A PE2022002787A PE20230859A1 PE 20230859 A1 PE20230859 A1 PE 20230859A1 PE 2022002787 A PE2022002787 A PE 2022002787A PE 2022002787 A PE2022002787 A PE 2022002787A PE 20230859 A1 PE20230859 A1 PE 20230859A1
- Authority
- PE
- Peru
- Prior art keywords
- dosage forms
- solid oral
- gonadotropin
- releasing hormone
- oral dosage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
Abstract
Referido a formas de dosificacion oral solida de combinacion que comprende: alrededor de 18 % a 22 % p/p de N-(4-(1-(2,6-difluorobencil)-5-((dimetilamino)metil)-3-(6-metoxi-3-piridazinil)-2,4-dioxo-1,2,3,4-tetrahidrotieno[2,3-d]pirimidin-6-il)fenil)-N'-metoxiurea, particularmente alrededor de 40 mg, o una sal farmaceuticamente aceptable de esta; alrededor de 0,3 % a 0,7 % p/p de estradiol; alrededor de 0,1 % a 0,4 % p/p de acetato de noretindrona; alrededor de 24 % a 28 % p/p de manitol; alrededor de 2 % a 6 % p/p de un almidon seleccionado del grupo que consiste en glicolato de almidon de sodio, almidon pregelatinizado, y una combinacion de lo anterior; alrededor de 0,5 % a 3 % p/p de hidroxipropilcelulosa; alrededor de 0,5 % a 3 % p/p de estearato de magnesio; alrededor de 38 % a 42 % p/p de monohidrato de lactosa; y alrededor de 1 % y 5 % p/p de un recubrimiento de pelicula. Formas de dosificacion oral solidas de combinacion de antagonistas de la hormona liberadora de gonadotropina. Tambien se refiere a un proceso para preparar dicha forma de dosificacion.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063032469P | 2020-05-29 | 2020-05-29 | |
| PCT/EP2021/064280 WO2021239917A1 (en) | 2020-05-29 | 2021-05-27 | Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20230859A1 true PE20230859A1 (es) | 2023-05-30 |
Family
ID=76305879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022002787A PE20230859A1 (es) | 2020-05-29 | 2021-05-27 | Formas de dosificacion oral solidas de combinacion de antagonistas de la hormona liberadora de gonadotropina |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230165800A1 (es) |
| EP (1) | EP4157227A1 (es) |
| JP (1) | JP2023528014A (es) |
| KR (1) | KR20230028732A (es) |
| CN (1) | CN115666531A (es) |
| AR (1) | AR122175A1 (es) |
| AU (1) | AU2021278303A1 (es) |
| BR (1) | BR112022023937A2 (es) |
| CA (1) | CA3185151A1 (es) |
| CL (1) | CL2022003338A1 (es) |
| CO (1) | CO2022019160A2 (es) |
| EC (1) | ECSP22098275A (es) |
| IL (1) | IL298587A (es) |
| MX (1) | MX2022015003A (es) |
| PE (1) | PE20230859A1 (es) |
| UY (1) | UY39229A (es) |
| WO (1) | WO2021239917A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3518933T (pt) | 2016-09-30 | 2022-05-10 | Takeda Pharmaceuticals Co | Métodos de tratamento de fibroides uterinos e endometriose |
| CN115068421B (zh) * | 2022-08-03 | 2023-08-04 | 南昌大学 | 一种瑞卢戈利纳米混悬液及其制备方法和应用 |
| CN115227648B (zh) * | 2022-08-03 | 2023-09-29 | 南昌大学 | 一种瑞卢戈利固体自微乳及其制备方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100360538C (zh) | 2003-01-29 | 2008-01-09 | 武田药品工业株式会社 | 噻吩并嘧啶化合物及其用途 |
| EP4119564A1 (en) | 2012-09-28 | 2023-01-18 | Takeda Pharmaceutical Company Limited | Production method of thienopyrimidine derivative |
| EP4233847A1 (en) | 2015-02-26 | 2023-08-30 | Takeda Pharmaceutical Company Limited | A tablet comprising a methoxyurea derivative and mannitol particles |
| JP7062673B2 (ja) | 2016-09-30 | 2022-05-06 | ミオバント サイエンシズ ゲーエムベーハー | 前立腺がんの治療 |
| PT3518933T (pt) | 2016-09-30 | 2022-05-10 | Takeda Pharmaceuticals Co | Métodos de tratamento de fibroides uterinos e endometriose |
-
2021
- 2021-05-27 CN CN202180037887.XA patent/CN115666531A/zh active Pending
- 2021-05-27 IL IL298587A patent/IL298587A/en unknown
- 2021-05-27 BR BR112022023937A patent/BR112022023937A2/pt unknown
- 2021-05-27 WO PCT/EP2021/064280 patent/WO2021239917A1/en unknown
- 2021-05-27 EP EP21730501.0A patent/EP4157227A1/en active Pending
- 2021-05-27 PE PE2022002787A patent/PE20230859A1/es unknown
- 2021-05-27 AU AU2021278303A patent/AU2021278303A1/en active Pending
- 2021-05-27 UY UY0001039229A patent/UY39229A/es unknown
- 2021-05-27 JP JP2022572798A patent/JP2023528014A/ja active Pending
- 2021-05-27 CA CA3185151A patent/CA3185151A1/en active Pending
- 2021-05-27 KR KR1020227046030A patent/KR20230028732A/ko active Search and Examination
- 2021-05-27 MX MX2022015003A patent/MX2022015003A/es unknown
- 2021-05-27 AR ARP210101422A patent/AR122175A1/es unknown
-
2022
- 2022-11-25 CL CL2022003338A patent/CL2022003338A1/es unknown
- 2022-11-28 US US18/070,341 patent/US20230165800A1/en active Pending
- 2022-12-28 CO CONC2022/0019160A patent/CO2022019160A2/es unknown
- 2022-12-29 EC ECSENADI202298275A patent/ECSP22098275A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL298587A (en) | 2023-01-01 |
| CN115666531A (zh) | 2023-01-31 |
| MX2022015003A (es) | 2023-03-03 |
| CA3185151A1 (en) | 2021-12-02 |
| CL2022003338A1 (es) | 2023-06-30 |
| UY39229A (es) | 2021-12-31 |
| BR112022023937A2 (pt) | 2022-12-27 |
| WO2021239917A1 (en) | 2021-12-02 |
| KR20230028732A (ko) | 2023-03-02 |
| EP4157227A1 (en) | 2023-04-05 |
| CO2022019160A2 (es) | 2023-03-27 |
| JP2023528014A (ja) | 2023-07-03 |
| ECSP22098275A (es) | 2023-01-31 |
| US20230165800A1 (en) | 2023-06-01 |
| AU2021278303A1 (en) | 2023-02-09 |
| AR122175A1 (es) | 2022-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20230859A1 (es) | Formas de dosificacion oral solidas de combinacion de antagonistas de la hormona liberadora de gonadotropina | |
| ES2521672T3 (es) | Formulaciones farmacéuticas para el tratamiento del cáncer | |
| CA2458067C (en) | Use of flibanserin in the treatment of sexual disorders | |
| AU2007263351B2 (en) | Tablets comprising candesartan cilexetil | |
| RU2013140484A (ru) | Фармацевтические композиции, содержащие аминосоединение | |
| NZ573382A (en) | Use of flibanserin for the treatment of post-menopausal sexual desire disorders | |
| JP2002524520A5 (es) | ||
| JP2007533687A (ja) | 月経前の及び他の女性の性的障害の治療におけるフリバンセリンの使用 | |
| UA72783C2 (en) | Agonist of central canabinoid receptors for preparation of drug disaccustoming smoking, combined pharmaceutical composition and kit | |
| JP2007169278A (ja) | Ｌｕｔｓ処置用の医薬組合せ | |
| ES2938261T3 (es) | Comprimido de ribociclib | |
| JP2016514102A5 (es) | ||
| CA2568445A1 (en) | Immediate release formulations of memantine oral dosage forms | |
| JP2023116489A5 (es) | ||
| JP2019536812A5 (es) | ||
| ES2349996T3 (es) | Preparado de liberación retardada en forma de pellas que contiene cinarizina y dimenhidrinato contra el vértigo. | |
| JP2015524828A5 (es) | ||
| JP6275645B2 (ja) | ４−メチル−３−［［４−（３−ピリジニル）−２−ピリミジニル］アミノ］−ｎ−［５−（４−メチル−１ｈ−イミダゾール−１−イル）−３−（トリフルオロメチル）フェニル］ベンズアミドの即放性製剤 | |
| JP4542777B2 (ja) | 肺高血圧症を予防または治療するのに用いられる医薬の製造のためのイルベサルタンの使用 | |
| JP4648193B2 (ja) | 医薬組成物 | |
| AR045330A1 (es) | Forma de dosificacion oral, procedimiento para su preparacion y uso del compuesto 5-(4-(2-(n-metil-n- (2-piridil)amino)etoxi )bencil) tiazolidin-2,4-diona o una sal o solvato farmaceuticamente aceptable del mismo para prepararla | |
| RU2019109050A (ru) | Композиции тезофензина | |
| CN113194950A (zh) | 早泄(pe)的治疗和预防 | |
| AU2012339829B8 (en) | Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation | |
| ES2286920B1 (es) | Derivados de aril (o heteroaril)azolilcarbinoles para el tratamiento de la fibromialgia. |